Vytrus Biotech (FRA:V5P) Total Receivables: €1.37 Mil (As of Dec. 2025)


FRA:V5P Vytrus Biotech SA FRA:V5P
63 GF Score
Price €16.70
GF Value €6.81
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Vytrus Biotech Total Receivables?

Vytrus Biotech FRA:V5P -2.34% 63 Total Receivables is €1.37 Mil as of Dec. 2025. GuruFocus rates FRA:V5P with a GF Score™ of 63/100 and a GF Value™ of €6.81 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Vytrus Biotech's Total Receivables for the quarter that ended in Dec. 2025 was €1.37 Mil.

Vytrus Biotech Total Receivables Related Terms

Vytrus Biotech Total Receivables Historical Data

* Premium members only.

The historical data trend for Vytrus Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vytrus Biotech Total Receivables Chart

Vytrus Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 0.27 0.53 0.78 0.72 1.37

Vytrus Biotech Semi-Annual Data
Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.78 0.72 1.42 1.37
FRA:V5P
63GF Score
Vytrus Biotech SA FRA:V5P
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vytrus Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €1.37 Mil mean?
Vytrus Biotech (FRA:V5P) has a Total Receivables of €1.37 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Vytrus Biotech and its competitors.
Is Vytrus Biotech's Total Receivables too high?
Vytrus Biotech's current Total Receivables is €1.37 Mil. Overall, Vytrus Biotech has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Total Receivables compare to VRTX and REGN?
Vytrus Biotech's Total Receivables of €1.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Vytrus Biotech and its competitors. Vytrus Biotech's current Total Receivables is €1.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (FRA:V5P) is currently considered Significantly Overvalued. The stock's GF Value™ is €6.81, compared to a current price of €16.70 — trading 145.2% above its estimated fair value. The current Total Receivables is €1.37 Mil. Vytrus Biotech's overall GF Score™ is 63/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Vytrus Biotech (FRA:V5P), the current Total Receivables is €1.37 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vytrus Biotech (FRA:V5P) Overvalued in 2026?

Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued. The current stock price of €16.70 is trading 145.2% above its estimated GF Value™ of €6.81. GuruFocus considers Vytrus Biotech to be Significantly Overvalued.

Key valuation signals for FRA:V5P:

  • Total Receivables: €1.37 Mil
  • GF Value™: €6.81 vs. price of €16.70 (145.2% above fair value)
  • GF Score™: 63/100 with 2 warning signs

No single metric tells the full story. See the FRA:V5P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vytrus Biotech Business Description

Other Exchanges VYT:Spain
Address Sant Gaieta 121, 2nd Floor, Terrassa, Barcelona, ESP, 08221
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
63GF Score

Get the complete analysis for FRA:V5P

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.70
Price
€6.81
GF Value